Outcome MeasureAnxiety

GAD-7

Generalized Anxiety Disorder 7-item Scale

22 Papers in Blossom

About This Instrument

The Generalized Anxiety Disorder 7-item (GAD-7) scale is a brief self-report questionnaire developed by Robert Spitzer and colleagues in 2006 to screen for and measure the severity of generalized anxiety disorder. Each of the 7 items asks how often the respondent has been bothered by a specific anxiety symptom over the past two weeks, rated 0–3 (not at all to nearly every day). Total scores range from 0 to 21. While developed for GAD, the scale also performs well as a screener for panic disorder, social anxiety disorder, and PTSD. The GAD-7 is widely used as a secondary endpoint in psychedelic clinical trials due to its brevity, free public-domain availability, and strong psychometric properties (sensitivity 89%, specificity 82% at cutoff ≥10). It is often paired with the PHQ-9 for combined depression and anxiety assessment.

Clinical Thresholds

021
Minimal
Score 04
Mild
Score 59
Moderate
Score 1014
Severe
Score 1521

Outcome Data Across Studies

Reported results for GAD-7 across 14 studies with quantitative data.

Outcome data across 52 study arm–timepoint observations
SD
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic
2021Secondary
Pre-COVID comparator(experimental)0160
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic
2021Secondary
COVID-19 period(experimental)0107
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic
2021Secondary
Pre-COVID comparator(experimental)141609.00.019
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic
2021Secondary
COVID-19 period(experimental)1410710.00.019
Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches
2023Secondary
Psychedelic approach(experimental)0518.4
Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches
2023Secondary
Psychedelic approach(experimental)7516.60.590
Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches
2023Secondary
Psychedelic approach(experimental)21515.20.970
Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches
2023Secondary
Psychedelic approach(experimental)42514.80.720
Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches
2023Secondary
Psycholytic approach(experimental)0516.0
Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches
2023Secondary
Psycholytic approach(experimental)7513.80.590

Papers Using GAD-7

Quick Facts

Full Name
Generalized Anxiety Disorder 7-item Scale
Domain
Anxiety
Papers Indexed
22
Score Range
021
Interpretation
Lower = better
Unit
points
Reference
Visit
All Measures